Yascha Khodamoradi1, Johanna Kessel, Jörg Janne Vehreschild, Maria J G T Vehreschild. 1. Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Johann Wolfgang Goethe University, Frankfurt am Main; Department of Internal Medicine, Hematology/Oncology, University Hospital Frankfurt, Johann Wolfgang Goethe University, Frankfurt am Main; Department I of Internal Medicine, University Hospital of Cologne, Center for Integrated Oncology Aachen, Bonn, Köln, Düsseldorf; German Center for Infection Research (DZIF), Bonn-Cologne.
Abstract
BACKGROUND: The introduction of industrially produced antibiotics was a milestone in the history of medicine. Now, almost a century later, the adverse consequences of these highly effective drugs have become evident in the form of antibiotic-resistant infections, which are on the rise around the world. The search for solutions to this problem has involved both the introduction of newer types of antibiotics and, increasingly, the development of alternative strategies to prevent infections due to multidrug-resistant bacteria. In this article, we review the pathophysiological connection between the use of antibiotics and the occurrence of such infections. We also discuss some alternative strategies that are currently under development. METHODS: This review is based on pertinent articles that appeared from January 2000 to April 2019 and were retrieved by a selective search in the PubMed database employing the search term "(microbiota OR microbiome) AND infection." Further suggestions by our author team regarding relevant literature were considered as well. RESULTS: The spectrum of preventive strategies encompasses measures for the protection of the intestinal microbiota (antimicrobial stewardship, neutralization of antibiotic residues in the bowel, use of phages and species-specific antibiotics) as well as measures for its reconstitution (prebiotics, probiotics, and fecal microbiota transfer). CONCLUSION: In view of the major problem that multidrug-resistant bacteria pose for the world's population and the resources now being spent on the search for a solution, derived both from public funding and from the pharmaceutical industry, we hope to see new, clinically useful approaches being developed and implemented in the near future.
BACKGROUND: The introduction of industrially produced antibiotics was a milestone in the history of medicine. Now, almost a century later, the adverse consequences of these highly effective drugs have become evident in the form of antibiotic-resistant infections, which are on the rise around the world. The search for solutions to this problem has involved both the introduction of newer types of antibiotics and, increasingly, the development of alternative strategies to prevent infections due to multidrug-resistant bacteria. In this article, we review the pathophysiological connection between the use of antibiotics and the occurrence of such infections. We also discuss some alternative strategies that are currently under development. METHODS: This review is based on pertinent articles that appeared from January 2000 to April 2019 and were retrieved by a selective search in the PubMed database employing the search term "(microbiota OR microbiome) AND infection." Further suggestions by our author team regarding relevant literature were considered as well. RESULTS: The spectrum of preventive strategies encompasses measures for the protection of the intestinal microbiota (antimicrobial stewardship, neutralization of antibiotic residues in the bowel, use of phages and species-specific antibiotics) as well as measures for its reconstitution (prebiotics, probiotics, and fecal microbiota transfer). CONCLUSION: In view of the major problem that multidrug-resistant bacteria pose for the world's population and the resources now being spent on the search for a solution, derived both from public funding and from the pharmaceutical industry, we hope to see new, clinically useful approaches being developed and implemented in the near future.
Authors: Tetyana Zakharkina; Ignacio Martin-Loeches; Sébastien Matamoros; Pedro Povoa; Antoni Torres; Janine B Kastelijn; Jorrit J Hofstra; B de Wever; Menno de Jong; Marcus J Schultz; Peter J Sterk; Antonio Artigas; Lieuwe D J Bos Journal: Thorax Date: 2017-01-18 Impact factor: 9.139
Authors: B D Huttner; V de Lastours; M Wassenberg; N Maharshak; A Mauris; T Galperine; V Zanichelli; N Kapel; A Bellanger; F Olearo; X Duval; L Armand-Lefevre; Y Carmeli; M Bonten; B Fantin; S Harbarth Journal: Clin Microbiol Infect Date: 2019-01-04 Impact factor: 8.067
Authors: Bastiaan W Haak; Eric R Littmann; Jean-Luc Chaubard; Amanda J Pickard; Emily Fontana; Fatima Adhi; Yangtsho Gyaltshen; Lilan Ling; Sejal M Morjaria; Jonathan U Peled; Marcel R van den Brink; Alexander I Geyer; Justin R Cross; Eric G Pamer; Ying Taur Journal: Blood Date: 2018-04-19 Impact factor: 25.476
Authors: Erik R Dubberke; Kathleen M Mullane; Dale N Gerding; Christine H Lee; Thomas J Louie; Harriet Guthertz; Courtney Jones Journal: Open Forum Infect Dis Date: 2016-06-20 Impact factor: 3.835
Authors: Victoria T Mücke; Kai-Henrik- Peiffer; Johanna Kessel; Katharina M Schwarzkopf; Jörg Bojunga; Stefan Zeuzem; Fabian Finkelmeier; Marcus M Mücke Journal: PLoS One Date: 2022-05-24 Impact factor: 3.752
Authors: Jan Kehrmann; René Scholtysik; Christian M Lange; Marcus M Mücke; Sabrina Rüschenbaum; Amelie Mayer; Victoria T Mücke; Katharina M Schwarzkopf; Stefan Zeuzem Journal: Gut Pathog Date: 2020-10-30 Impact factor: 4.181